PreveCeutical Files International Patent Application for Sol-Gel Cannabinoid Formulation for Antiviral Use
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed an international patent application on November 19, 2021, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use" (the "Invention"), claiming priority from Australian patent application number 2020904291. The patent is for an invention that relates to an antiviral cannabinoid-containing...
2021-11-29 8:00 AM EST
PreveCeutical Files Provisional Patent Application for D-Amino Acid Peptides
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on November 18, 2021, entitled "Peptides and Uses Thereof", application number 2021903722, with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer. Compounds...
2021-11-24 8:00 AM EST
PreveCeutical Signs License Agreement for Exclusive Rights to Use UniQuest's Sol-Gel Technology for Delivery of Cannabinoids
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), is pleased to announce that it has signed a license agreement with UniQuest Pty Ltd. ("UniQuest") giving PreveCeutical exclusive rights to UniQuest's Sol-Gel ("Sol-Gel License") technology for the delivery of cannabinoids. The licence agreement provides PreveCeutical with the right to use the technology to deliver cannabinoids...
2021-11-18 8:00 AM EST
Caroline MacCallum, MD, FRCPC, BSc Pharm, Joins PreveCeutical
Vancouver, British Columbia--(Newsfile Corp. - October 5, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is very pleased to announce the appointment of Dr. Caroline MacCallum as a senior advisor and consultant for the Company. Dr. MacCallum will be working with our team on the development and commercialization of the Company's Cannabinoid Sol-gel products. Her specialization in internal medicine and expertise in complex pain and...
2021-10-05 8:00 AM EDT
PreveCeutical Receives AU$315,338 Research & Development Tax Incentive Cash Refund
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received a AU$315,338 cash rebate from the Australian Federal Government's Research and Development ("R&D") Incentive Program. The cash refund is related to expenditure on eligible Australian R&D activities conducted during the financial year ended December 31, 2020. The R&D activities were...
2021-08-31 8:00 AM EDT
PreveCeutical Files International Patent Application for its Dynorphin Peptides
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed an International PCT application on July 1, 2021, entitled "Peptides and uses thereof", application number PCT/AU2021/050707 with the aim of seeking protection for certain peptides and their use in pain management. There is a need for the development of new drugs that are effective in pain...
2021-07-07 8:00 AM EDT
PreveCeutical Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is pleased to provide the following update. The Company's highest priority is to create shareholder value through the development and commercialization of products and delivery technology. The Company has partnered with UniQuest Pty Limited and the University of Queensland through its Australian subsidiary, PreveCeutical (Australia)...
2021-05-31 8:00 AM EDT
PreveCeutical Appoints Founding Director of RAS Life Science Solutions Aditya Bahl as Advisor
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the appointment of Aditya Bahl as an advisor and consultant for the Company. Mr. Bahl brings over 20 years of experience in pharmaceutical marketing and clinical development. He is the CEO and founder of RAS LSS, a boutique healthcare consulting group based in Germany. He provides strategic guidance to...
2021-03-15 8:00 AM EDT
PreveCeutical Announces Debt Settlement and Conversion of Debt
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has agreed to issue 19,554,201 common shares without par value in its capital (each, a "Share") to two non-arm's length creditors and an arm's length creditor of the Company at a deemed issuance price of $0.032 per Share. The Company entered into shares for debt settlement agreements with a current director and a...
2021-03-12 7:59 PM EST
Accomplished Biophysicist Linnéa Olofsson, Ph.D. joins PreveCeutical
Vancouver, British Columbia--(Newsfile Corp. - February 23, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is very pleased to announce the appointment of Dr. Linnéa Olofsson as an advisor and consultant for the Company. Dr. Olofsson will be working with our team in implementing our strategies for the commercialization of our products. With her scientific background and ability to understand the needs in the medical field, she will...
2021-02-23 8:00 AM EST
PreveCeutical Announces Completion of Pain Management Peptides Program
Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) - PreveCeutical Medical Inc (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce the successful completion of its non-addictive analgesic program ("Analgesic Program"). The Analgesic Program started in July 2018 to discover and develop peptide-based therapeutics for moderate to severe pain and inflammation. The Company has received the final research project report from UniQuest Pty...
2021-02-02 8:00 AM EST
PreveCeutical files Provisional Patent Application for its BSV Peptide
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on December 22, 2020, entitled "Cyclic Peptides and Uses Thereof", application number 2020904798, with the aim of seeking protection for certain cyclic peptides and their use in prevention and treatment of brain cancer. Peptides derived...
2021-01-05 8:00 AM EST
Successful Completion of the COVID-19 Sol-Gel Formulation Development
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce the successful laboratory development of a cannabinoid Sol-Gel formulation ("SARS-CoV-2 Sol-Gel") as a potential prevention/treatment for COVID-19 caused by SARS-CoV-2 infection. Independent scientific literature has reported that high CBD strains could potentially have beneficial properties for the prevention/treatment...
2020-11-25 8:00 AM EST
PreveCeutical Files Provisional Patent Application for its COVID-19 Formulation
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on November 20, 2020, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use", application number 20200904291, with the aim of seeking protection for certain cannabinoid formulations and their use in prevention and treatment of...
2020-11-23 7:30 AM EST
PreveCeutical Provides Update on Its COVID-19 Cannabinoid Sol-Gel Program
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to provide an update on its COVID-19 Cannabinoid Sol-Gel Program ("COVID-19 CBD Program") (see news release dated May 4, 2020). With the successful completion of the COVID-19 CBD Program, a sol-gel based formulation has been developed to deliver medicinal cannabis. The Company will provide further information once the final report...
2020-11-10 7:00 AM EST
PreveCeutical Receives Extension of Six Months to Hold its Annual General Meeting from the Registrar of Companies, British Columbia
Vancouver, British Columbia--(Newsfile Corp. - October 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has been granted an extension of six months by the Registrar of Companies, to hold its Annual General Meeting ("AGM")for the year 2020 under section 182(4) of the Business Corporations Act. The six months extension is from October 29, 2020, to April 29, 2021. With the challenges related to COVID-19, the...
2020-10-29 3:38 PM EDT
PreveCeutical's Application for COVID-19 Therapy Funding Update
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") informs that in reference to its current work to develop medical countermeasures in response to COVID-19 (News Release dated May 4, 2020), PreveCeutical has received notification from the Strategic Innovation Fund ("SIF") that its proposal, which was part of the second phase of Canada's National Medical Research Strategy in response to COVID-19,...
2020-10-09 4:15 PM EDT
Veteran Johnson & Johnson Executive Dr. Ajit Shetty Joins PreveCeutical
Vancouver, British Columbia--(Newsfile Corp. - October 1, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is very pleased to announce the appointment of Dr. Ajit Shetty as an advisor and consultant for the Company. Dr. Shetty brings his extensive pharmaceutical experience leading commercial and supply chain operations and his significant educational background to the Company. Dr. Shetty spent 36 years at Johnson & Johnson ("J&J") in...
2020-10-01 11:36 AM EDT
PreveCeutical Provides Lead Pain Management Peptides Update
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide a further update to its non-addictive analgesic program ("Analgesic Program"). Further to the news release of September 2, 2020, the Analgesic Program consisted of an iterative approach to peptide design resulting in a number of second-generation peptide analogues optimized from the most promising...
2020-09-08 7:00 AM EDT
PreveCeutical Announces Lead Pain Management Peptides Identified for Preclinical Evaluation
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update to its non-addictive analgesic program ("Analgesic Program"). The Analgesic Program started in July 2018 to discover and develop analgesic peptide-based therapeutics for moderate to severe pain and inflammation. This discovery program, which utilizes a proprietary disulfide linker technology, is...
2020-09-02 7:00 AM EDT